<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890045</url>
  </required_header>
  <id_info>
    <org_study_id>11-0004</org_study_id>
    <nct_id>NCT00890045</nct_id>
  </id_info>
  <brief_title>Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study</brief_title>
  <official_title>A Comparison Between the HeROÂ® Graft and Conventional Arteriovenous Grafts in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemosphere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hemosphere, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the HeRO Vascular Access Device to a conventional ePTFE graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the HeRO Vascular Access Device to a conventional
      ePTFE graft. It is hypothesized that HeRO patency will be comparable to the conventional
      ePTFE graft control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loss of HeRO secondary patency compared to control</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loss of HeRO primary patency compared to control</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HeRO serious device or implant procedure-related adverse events compared to control</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Renal Failure Chronic Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Control graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional ePTFE hemodialysis graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HeRO Vascular Access Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HeRO Vascular Access Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeRO Vascular Access Device</intervention_name>
    <description>HeRO Vascular Access Device</description>
    <arm_group_label>HeRO Vascular Access Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional ePTFE hemodialysis graft</intervention_name>
    <description>Conventional ePTFE hemodialysis graft</description>
    <arm_group_label>Control graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 21 years of age or older.

          2. Male or non-pregnant female.

          3. Life expectancy 2 years.

          4. End-stage renal disease requiring an arm vascular prosthesis for dialysis access.

          5. Ability to understand and provide written informed consent.

          6. Willing and able to cooperate with follow-up examinations.

          7. Subject's upper arm can be used for implant (Note: The GVAS device must be implanted
             in the upper arm only, but the Control group graft can be implanted in the upper or
             lower arm location.).

          8. Able to follow a daily aspirin and/or other oral anticoagulation/antiplatelet regimen.

        Exclusion Criteria:

          1. Potential graft target artery less than 3 mm in diameter determined by any suitable
             preoperative measure.

          2. Documented history of drug abuse within six months.

          3. &quot;Planned&quot; concomitant surgical procedure or previous major surgery within 30 days,
             excluding vascular access related procedures.

          4. Currently being treated with another investigational device or drug.

          5. Known bleeding diathesis or hypercoagulable state.

          6. Peripheral white blood cell count 1500/mm3 (1.5 K/mm3) or platelet counts 50,000/mm3
             (50 K/mm3).

          7. Degenerative connective tissue disease, e.g., Marfan's and Ehlers Danlos Syndrome.
             Subjects with Lupus Erythematosus may be included.

          8. Subjects with known or suspected concomitant bacterial, fungal, viral, or parasitic
             infection. Subjects with Hepatitis B may be included. Subjects who are HIV + with CD4
             count of &lt;200 are excluded.

          9. Severe underlying co-morbidity or immediate life-threatening condition.

         10. Subjects with any condition which, in the opinion of the investigator, could preclude
             evaluation of response or completion of follow-up or affect subject safety.

         11. Subjects who are candidates for autologous fistulas.

         12. Subjects with scheduled renal transplant within the next 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Glickman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sentara Heart Hospital, Norfolk, VA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Cedars Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois Unversity</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton/Brackenridge Hospitals</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Medical Center/Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Heart Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nassar GM, Glickman MH, McLafferty RB, Croston JK, Zarge JI, Katzman HE, Peden EK, Lawson JH, Martinez JM, Thackeray L. A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients. Semin Dial. 2014 May-Jun;27(3):310-8. doi: 10.1111/sdi.12173. Epub 2014 Jan 15.</citation>
    <PMID>24428351</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular access hemodialysis</keyword>
  <keyword>ePTFE graft</keyword>
  <keyword>Graft-eligible</keyword>
  <keyword>Long-term vascular access for hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

